Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS: We conducted a randomized, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to have an LDL cholesterol level of at least 70 mg per deciliter while they were receiving maximally tolerated statin therapy with or without additional lipid-lowering therapy. (Maximally tolerated statin therapy was defined as the highest intensity statin regimen that a patient was able to maintain, as determined by the investigator.) Patients were randomly assigned in a 2:1 ratio to receive bempedoic acid or placebo. The primary end point was safety, and the principal secondary end point (principal efficacy end point) was the percentage change in the LDL cholesterol level at week 12 of 52 weeks. RESULTS: The trial involved 2230 patients, of whom 1488 were assigned to receive bempedoic acid and 742 to receive placebo. The mean (±SD) LDL cholesterol level at baseline was 103.2±29.4 mg per deciliter. The incidence of adverse events (1167 of 1487 patients [78.5%] in the bempedoic acid group and 584 of 742 [78.7%] in the placebo group) and serious adverse events (216 patients [14.5%] and 104 [14.0%], respectively) did not differ substantially between the two groups during the intervention period, but the incidence of adverse events leading to discontinuation of the regimen was higher in the bempedoic acid group than in the placebo group (162 patients [10.9%] vs. 53 [7.1%]), as was the incidence of gout (18 patients [1.2%] vs. 2 [0.3%]). At week 12, bempedoic acid reduced the mean LDL cholesterol level by 19.2 mg per deciliter, representing a change of -16.5% from baseline (difference vs. placebo in change from baseline, -18.1 percentage points; 95% confidence interval, -20.0 to -16.1; P<0.001). Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy. CONCLUSIONS: In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CLEAR Harmony trial assessed bempedoic acid’s safety and efficacy in 2230 statin-treated patients with atherosclerosis or HeFH compared with placebo [130]. Relative to placebo, bempedoic acid reduced LDL-C by − 16%, non-HDL-C by − 13%, total cholesterol by − 11%, ApoB-100 by − 12% and hsCRP by − 22%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“The incidence of adverse events was similar across both interventional groups, yet a higher percentage discounted treatment with bempedoic acid than placebo (10.9% versus 7.1%). Gout was more frequently observed among patients treated with bempedoic acid (1.2% versus 0.3%).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“Safety findings in the real-world setting were generally aligned with those reported in RCTs and meta-analyses [[12], [13], [14], [15],17,18], although reporting was limited and inconsistently captured.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
McGowan, M. W., Artiss, J. D., Strandbergh, D. R., & Zak, B. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.538 · Cited by 1,298
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Self-citation
Cited by
Items 701–800 of 807
Advanced therapeutics for targeting atherosclerosis
Bhunia, S. S., & Debnath, U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99988-5.00005-x
[Advances in diagnosis and treatment of familial hypercholesterolemia].
Zheng, H., Jiang, S., & Li, L. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.01.22
Lipidmanagement 2022 – von der Tradition zur Innovation
Reibis, R. K. (2023) · Aktuelle Kardiologie · doi:10.1055/a-2005-5248
“Phase-III-Wirksamkeitsstudien zeigten im CLEAR-Programm sowohl für die isolierte Gabe bei Statinintoleranz als auch additiv zum Statin oder als Kombinationstherapie mit Statin/Ezetemib eine konsistente Senkung der LDL-CSpiegel [13].”
BackgroundCatapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00022-4
Self-citationBond, R. M., & Ferdinand, K. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00039-x
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Bempedoinsäure bei Niereninsuffizienz
Grützmacher, P. (2023) · Die Nephrologie · doi:10.1007/s11560-023-00667-1
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant
Doggrell, S. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2242259
Novel therapies in clinical use for the management of hyperlipidaemia
Mettananda, C. D. (2023) · Asian Journal of Internal Medicine · doi:10.4038/ajim.v2i2.105
Bempedoic acid, when and how to use it?
Masson, W. M., Nogueira, P., & Giraldo, G. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000213
Nuevos fármacos hipolipemiantes
Deibe, F. I. L., Rodríguez, R. D. R., García, M. C., Blanco, C. S., & Peña, P. M. (2023) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2023.04.008
Management of Cardiovascular Disease in the Elderly
Onuorah, I., Agrawal, A., & WENGER, N. K. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_25-1
Campbell, L. A., Ammon, J. P., & Jackson, C. (2024) · Southern Medical Journal · doi:10.14423/smj.0000000000001636
Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update
Çaklılı, Ö. T., Rizzo, M., & Cesur, M. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611290763240126045433
Treatment of dyslipidemia in acute coronary syndrome
Yadav, S., & Sawhney, J. P. S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.011 · Cited by 3
Management kardiovaskulärer Risikofaktoren
Weiss, N., & Dörr, G. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-61379-5_16-1
A narrative review of treatment modalities for familial hypercholesterolemia
Samprokatsidis, G., Antza, C., Frangou, D., & Kotsis, V. (2023) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1054
Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy
Fernández-Vázquez, D., Weideman, S. G., & Banerjee, S. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.02.002
“CLEAR ADVANTAGE” FROM TARGETING INFLAMMATION RISK OVER LDL RISKPreprint
Kaesemeyer, W. (2024) · doi:10.22541/au.171015614.43591808/v1
Gollmer, J., Zirlik, A., & Bugger, H. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2226-0683
“D i a b e t e s Prävention/Therapie [14, 15].”
Background张, 卓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451662
Badshah, A., Asif, M., Jamil, E., Almas, M., Mehboob, Z., Zainab, Z., Faisal, M., Abubakar, M., & Ullah, M. (2024) · Hamdard Journal of Pharmacy · doi:10.61744/hjp.v3i2.74
Использование бемпедоевой кислоты в клинической практике
Курочкина, Н. С., Зубарева, М. Ю., Р., А. А., & Владимирович, С. И. (2024) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2024.03.0002
Ntaios, G., & Dalakoti, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.10.012
Saladini, F., Baggio, S., Marcato, F., Campisi, F. C., Verlato, R., Pasquetto, G., Bertaglia, E., Povolo, G., Buja, P., & Ferri, N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247505
“This drug [26,27] showed an additional reduction of 19.2 mg/dL (0.5 mmol/L) of LDL level in comparison to the placebo ( p < 0.001), during 12 weeks of follow up, among patients who had an LDL level of 70 mg/dL (1.81 mmol/L) with or without lipid-lowering therapy [25]; and among patients with…”
InfluentialAgnello, F. G., Russo, C., Laterra, G., Ingala, S., Saragoni, S., Giuffrida, M., Greca, P. M., Tona, F. L., Rinaldi, N., Gagliano, I., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.12.027
Lipid-lowering drugs: present and future
Selizarova, N. O., Михайловна, Н. С., Anisimova, N. A., Buyuklinskaya, O. V., Bolotova, V. T., & Okovityi, S. V. (2024) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf632629
Ross, L. J. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2024.11.011
Shehab, H. F., Rajan, R., Al‐Jarallah, M., Dashti, R., Al-Sarraf, A. J., Alsaber, A., Tse, G., AlObaid, L., & Lansberg, P. J. (2025) · Annals of Clinical Cardiology · doi:10.4103/accj.accj_28_24
Hoogendijk, J. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00380-8
Bempedoic Acid in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis
Samajdar, S. S., Sarkar, S., Chakraborty, S., Sarkar, D., Ghosh, S., Banerjee, S., Biswas, K., Pal, J., Chatterjee, N., Bandyopadhyay, S. K., et al. (2025) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_576_24 · Cited by 1
Use of bempedoic acid in an out-patient setting: an assessment of efficacy heterogeneityPreprint
Maarouf, A., Shergill, M. K., Jones, A. F., Marriott, J. F., & Ramachandran, S. (2025) · Research Square · doi:10.21203/rs.3.rs-6727985/v1
Garjón, J. (2025) · Boletín de información farmacoterapéutica de Navarra · doi:10.54095/bitn20253202
Kennedy, C., Conroy, L., Millar, B., & de Gaetano, M. (2025) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2025.187
Арманович, А. А., Kaktursky, L. V., Urazova, O. I., Трофименко, А. И., Sukiasyan, L. M., Коган, Е. А., Демура, Т. А., & Вачиковна, П. Н. (2025) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-2-124-140 · Cited by 1
Management kardiovaskulärer Risikofaktoren
Weiss, N., & Dörr, G. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60880-7_16
Puertas-Umbert, L., Alonso, J., Blanco-Casoliva, L., Bentanachs, R., Asmarats, L., Arderiu, G., Martínez‐González, J., & Rodríguez, C. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500856
¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
Cuevas, A. E., & Asumendi, P. D. (2025) · Actualización en Medicina de Familia · doi:10.55783/amf.s210912
Hypolypidemic therapy in the XXI century: what is new?
Ob’edkova, N. Y., Usacheva, D. N., Mal, G. S., & Геннадьевич, О. Е. (2024) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2024-28-1-153-171
Tratamiento de la angina estable
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Álvarez, D. I., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.003
Protocolo de prevención primaria y secundaria de la cardiopatía isquémica
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Iglesias-Álvarez, D., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.008
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Von Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
Efek Asam Lemak Omega-3 pada Pemulihan dari Prosedur Kardiovaskular
Djaja, N., Soekiono, C. J., & Vanessa, I. (2026) · Jurnal Sains dan Kesehatan · doi:10.30872/jsk.v6i3.955 · Cited by 2
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336387
Wang, X., Zhang, Y., Tan, H., Wang, P., Zha, X., Chong, W., Zhou, L., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.12799011
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336375
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336381
FILIPPO, O. D., ́ascenzo, F. D., Iannaccone, M., Bertaina, M., Leone, A., Borzillo, I., Ravetti, E., Solano, A., Pagliassotto, I., Nebiolo, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26646505
FILIPPO, O. D., D’Ascenzo, F., Iannaccone, M., Bertaina, M., Leone, A., Borzillo, I., Ravetti, E., Solano, A., Pagliassotto, I., Nebiolo, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26646502
Samburov, A. V., Khaibulina, N. A., Kulik, T. L., & Галеев, Ш. Р. (2026) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2025-4-158-172
Bempedoic acid: a novel lipid-lowering pharmacological agent for the management of dyslipidemia
Abdul-Husseein, H. K. (2026) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1089
Musculoskeletal Adverse Events Associated With Bempedoic Acid: A Real-World Pharmacovigilance Study
He, Y., Wei, Y., Jiang, X., & Lu, J. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001792 · Cited by 1
The year in cardiology: Cardiovascular prevention
Ray, K. K., Laufs, U., Cosentino, F., Lobo, M. D., & Landmesser, U. (2019) · Srce i krvni sudovi · doi:10.5937/siks1904184r
Self-citationThe year in cardiology: Cardiovascular prevention
Ray, K. K., Laufs, U., Cosentino, F., Lobo, M. D., & Landmesser, U. (2019) · Srce i krvni sudovi · doi:10.5937/siks1902107r
Self-citationHow to Evaluate and Reduce Micro- and/or Macrovascular Residual Risk?
Hermans, M. P., Lurquin, F. O., Ahn, S. A., Rousseau, M. F., & (R3i), O. B. O. T. R. R. R. I. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_24
Iskra, R., & Liubas, N. (2025) · Biointerface Research in Applied Chemistry · doi:10.33263/briac156.083
Dyslipidemia Management in Older Adults
Krishnamurthy, A., & Kim, S. M. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.003
Li, Q., Fan, M., Gao, A., & Qin, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1765949
“Hypercholesterolemia is a metabolic disorder characterized by elevated blood cholesterol, particularly LDL-C (12).”
InfluentialHsieh, I.-C., Chen, D., Chu, C. L., Chang, Y., Tzeng, B., Huang, T., Lin, H., Chuang, W.-P., Huang, C.-C., Yeh, J., et al. (2026) · medRxiv · doi:10.64898/2026.02.06.26345788
Saad, M., Shehri, M. A., El-Gazzar, A., Senara, M., & Taha, H. (2026) · Cureus · doi:10.7759/cureus.103992 · Cited by 1
Gupta, G., Sindhu, S., Jain, A., Rajan, K., Hyanki, C., Bhandari, M., Pradhan, A. K., Kumar, R., & Dixit, R. K. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_543_2025
Vanhulle, A., Yurdaer, D., Calster, L. V., Willems, A., Moerman, V., & Sutter, J. D. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2638804
“Both agents significantly reduce LDL-C levels: bempedoic acid lowers LDL-C by ~17% on top of statins (CLEAR Harmony [9] and CLEAR Wisdom [10]) and by ~36% in fixed-dose combination with ezetimibe [11], with comparable effects observed in HeFH subgroups.”
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 2
“The CLEAR Harmony study involved patients receiving maximally tolerated statin therapy trial and bempe-doic acid lowered LDL-C levels by 18.1% compared with placebo at week 12 [88].”
InfluentialEffect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes
Brandts, J., & Ray, K. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00019-7
Self-citationEvaluation of bempedoic acid in elderly patients: real-world evidence from the REALIST study
Muscoli, S., Marco, E. D., Puttini, F., Ghezzi, S. S., Ifrim, M., Amtaeh, M., Renga, E. M., Cappello, C. M., Barone, G., Chiricolo, G., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1675989 · Cited by 1
Puertas-Umbert, L., Alonso, J., Blanco-Casoliva, L., Bentanachs, R., Asmarats, L., Arderiu, G., Martínez-González, J., & Rodriguez, C. R. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500856
Novokhatskaya, E. A., Ershova, A. I., & Drapkina, O. M. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2026-4742
Statin Prescription Patterns: A Cross-sectional Study
Sharma, S. M., Keerthana, M., Aparnavi, P., Sekkizhar, U., Shanmugam, J., & Palanisamy, K. T. (2026) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636261427909
“40,41 As the study population predominantly comprised younger physicians, the findings may not be generalizable to senior physicians.”
Peng, A. W., Plott, C. F., Zahid, S., Kassamali, A. A., Jones, L. K., Campbell‐Salome, G., Davis, E. N., Head, L., Kalich, B. A., Spitz, J. A., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107440 · Cited by 1
Manshadi, M. D., Setoodeh, P., & Zare, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.19.716936
“Bempedoic acid, a clinically approved lipid-lowering drug used in patients with hypercholesterolemia (32), was selected as the ACLY inhibitor.”
Familiäre Hypercholesterinämie – wann daran denken – wie vorgehen?
Vogt, A. (2026) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-026-00304-x
“In einer Studie, in die auch wenige Teilnehmer mit heFH eingeschlossen waren, wurde LDL-C bis zu 16,5% gesenkt [21].”
Rhabneh, L., Ababneh, R., Alnaser, I., Aloqaily, M., Alfarrajin, I., Al-Badawi, I. A., & Amawi, A. (2026) · Polski Merkuriusz Lekarski · doi:10.36740/merkur202602114
Metabolic Implications in Cardio-Renal Syndromes
Timar, B., Gaiţă, L., Avram, V. F., & Braha, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_15
Chinese expert consensus on the choice of initial cholesterol-lowering strategy
Wu, N., Wang, X., Ye, P., Chen, H., Chen, Z., Zhao, D., Dq, P., Guo, Y., Gao, Y., Yang, J.-G., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798787
“This combination therapy may be considered as an initial cholesterol-lowering strategy for high-risk patients with ASCVD, HeFH, or multiple CVD risk factors.”
InfluentialKitamoto, R., Isogai, Y., & Shimano, H. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66057
Cersosimo, A., Rovelli, R., Drera, A., Gorga, E., Brangi, E., Metra, M., & Vizzardi, E. (2026) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001873 · Cited by 1
Mesquita-Lousada, A., Rocha-Melo-Sousa, A., Teixeira, C., Guimarães, T. R., Marques-Vieira, M., Andrade, J. P., Ribeiro, H., Neiva‐Sousa, M., & Rocha-Neves, J. P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114205
“…demonstrated substantial additional LDL-C reductions in landmark clinical trials, with PCSK9 inhibitors lowering LDL-C by approximately 50–60% [6,7], inclisiran by 40–51% [8], and bempedoic acid by 17–21% [9,10], thereby expanding the possibilities for achieving guideline-recommended targets [11].”
Waller, J. R., & Davis, E. (2026) · Medicine · doi:10.1016/j.mpmed.2026.04.009
Alaspure, A. C., Yadav, A. D., Lodha, S. R., Gore, A. H., Nilewar, S. S., Harde, M. T., Patole, S., & Gorde, P. L. (2026) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2026.2685477
“Given its unique mechanism, Bempedoic acid has proven effective in reducing LDL cholesterol levels in patients who cannot achieve optimal lipid control with statins alone [16–18].”
Mancini, G. B. J., Lincoff, A. M., Goldberg, A. C., Broestl, C., Li, N., Duell, P. B., Laufs, U., Catapano, A. L., Leiter, L. A., Banach, M., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047897 · Cited by 1
“In 2 trials, 90% of patients received moderate-or high-intensity statins (CLEAR Wisdom [NCT02991118], CLEAR Harmony [NCT0266666]), 12,14 while patients who were statin intol-erant were included in the long-term cardiovascular outcomes trial (CLEAR Outcomes [NCT02993406]).”
Self-citationThe Role of Lipid Disorders in Cardiovascular Mortality Among Saudis: A Review Perspective
Alsaidan, A. A. (2026) · International Journal of Endocrinology · doi:10.1155/ije/5596073
“Bempedoic acid functions as an inhibitor of ATP-citrate lyase in the liver to achieve LDL-C reduction be-tween 18% and 24% alone and up to 40% when used with eze-timibe while maintaining safety for statin-intolerant patients [50].”
Lipid-lowering for people with chronic kidney disease: a narrative review
Tunnicliffe, D. J., Krishnasamy, R., & Strippoli, G. F. (2026) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2024.000059
Osman, M. M., Massad, T., Sims, O. T., & Chiang, D. J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.026
Kronenberg, F., Höllerl, F., Brath, H., Rega‐Kaun, G., Greber‐Platzer, S., Weiser, C., Klein, D. P., Riesenhuber, N., Binder, C. J., Brix, J. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02760-6
Duan, Y., Gong, K., & Wang, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34186-1.01002-1
Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort
Jiménez, D. L., Martínez‐Hervás, S., Martínez, N. L., Jericó, C. R., Martínez-Soriano, M. J., Royuela, M., Franco‐Moreno, A., Rodríguez-Carnero, G., Varona, J. F., Molinero, A. M., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.033
Gómez-Barrado, J., Gómez-Turégano, P., Turégano-Yedro, M., Jiménez-Baena, E., Fernández-Chamorro, A. I., & Gómez-Turégano, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156102
“Randomized clinical trials from the CLEAR program have demonstrated that BA significantly reduces LDL-C levels and improves cardiovascular outcomes, particularly in statin-intolerant individuals [10–13].”
Carmo, M., Sazatornil, M. R. A., Martín-Conde, J. A., Iglesias, E. A., & Prieto, J. M. M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0353193
Cardiovascular Risk Factors in Youth
Khoury, M., & Urbina, E. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11851-7.00015-x
Garg, N., Jaiswal, A., Kapoor, A., Tewari, S., Khanna, R., Sahu, A., Katheria, A., Nazir, A., & Jaiswal, A. (2026) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2026.08.009
Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets
Ponte-Negretti, C. I., Lorenzatti, A. J., Wyss-Quintana, F. S., Alonso, R., Méndez-Castillo, M., Valdez, O., Ullauri-Solórzano, V. E., Ullauri-Valcárcel, C. Y., Puente-Barragán, A., Zárate-Correa, L. C., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1894845 · Cited by 1
ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential
Wang, W., Li, X., Shi, H., Song, G., Xie, Z., & Li, J. (2026) · iNew Medicine · doi:10.1002/inm3.70077
THE LATEST APPROACHES TO DYSLIPIDEMIA MANAGEMENT. A NARRATIVE REVIEW
Pawełkiewicz, S., Łysak, K., Fimiarz, K. J., Grygutis, I., Jarzęcka, U., Suchołbiak, A., Lachowski, F. R., Kozielec, M., Kozielec, K., & Górak, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5647
Autosomal Recessive Hypercholesterolemia Due to a Novel Homozygous LDLRAP1 Frameshift Mutation
Gitte, P. T., Kharche, M. N., & Khedkar, U. B. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.110329
Epigenomic Remodeling by Lipid Metabolism: A Cross-Disease Perspective on Cancer and Brain Disorders
Rafique, A., Farooq, A., Cho, C. E., & Bakovic, M. (2026) · Genes · doi:10.3390/genes17091134
Haberbosch, L., Baessler, A., de Ruiter, U., Sinning, D., Katzmann, J. L., Könemann, S., Schatz, U., Mai, K., Kassner, U., & Bobbert, T. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-03062-6
Bempedoic Acid: From Guidelines to the Real World
Zimodro, J. M., & Gouni‐Berthold, I. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.3.381 · Cited by 1
“62 The LDL-C-lowering effect was more pronounced in women than in men (−22.3% vs. −17.4%, p =0.03) in the latter, 61 while no differences between subgroups were identified in the former trial.”
InfluentialMatteucci, A., Bonanni, M., Fusco, S. A. D., Aiello, A., Aquilani, S., Fedele, S., Nardi, F., & Colivicchi, F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.012
Hu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
Metadata
- Authors
- Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922038538
- Cited by
- 807
- References
- 20
- Citations by year
- 2026: 77 · 2025: 87 · 2024: 114 · 2023: 143 · 2022: 116 · 2021: 107 · 2020: 107 · 2019: 53
- FWCI
- 91.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, LDL cholesterol lowering, ATP-citrate lyase inhibitor, hypercholesterolemia, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, statin therapy, gout, adverse events, drug safety, lipid-lowering therapy, long-term treatment, gout risk, statin intolerance
- MeSH terms
- Aged, Apolipoproteins B, ATP Citrate (pro-S)-Lyase, C-Reactive Protein, Cholesterol, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Female, Humans, Hypercholesterolemia, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.